• 생물정신의학
• /
• 제3권1호
• /
• pp.83-87
• /
• 1996

The effects of disulfiram implantation therapy have three components : placebo, pharmacological, and psychological effects, However, considering the fact that there is no reported DER(disulfiram-ethanol reaction) in placebo implanted patients and the absorption of implanted disulfiram is not sufficient to produce DER, the major effect of disulfiram implantation is psychological rather than placebo and pharmacological one, Recently, there have been great efforts to develop a new farm of disulfiram which could exert a real pharmacological effect through the heightened bioavailability, To illustrate several examples, there are copolymer consisting of disulfiram and polymer such as polyethylene glycol and PLGA(polyglycolic-co-L-lactic acid) and depot in which disulfiram is dissolved into saline solution containing 5% w/v carboxymethylcellulose or 0.1% polysorbate 80. On the other hand, there has been a continuous research about Me-DTC, an active metabolite of disulfiram, which inhibit ALDH (acetaldehyde dehydrogenase) more potently even at a smaller amount than disulfiram. In the future. In is hoped to develop a new form of disulfiram with high bioavailability at a small amount.

• Genomics & Informatics
• /
• 제12권4호
• /
• pp.151-155
• /
• 2014

In November 2013, the US Food and Drug Administration (FDA) sent a warning letter to 23andMe, Inc. and ordered the company to discontinue marketing of the 23andMe Personal Genome Service (PGS) until it receives FDA marketing authorization for the device. The FDA considers the PGS as an unclassified medical device, which requires premarket approval or de novo classification. Opponents of the FDA's action expressed their concerns, saying that the FDA is overcautious and paternalistic, which violates consumers' rights and might stifle the consumer genomics field itself, and insisted that the agency should not restrict direct-to-consumer (DTC) genomic testing without empirical evidence of harm. Proponents support the agency's action as protection of consumers from potentially invalid and almost useless information. This action was also significant, since it reflected the FDA's attitude towards medical application of next-generation sequencing techniques. In this review, we followed up on the FDA-23andMe incident and evaluated the problems and prospects for DTC genetic testing.

• 폴리머
• /
• 제26권5호
• /
• pp.623-633
• /
• 2002

적인을 이용한 ortho-cresol novolac (OCN)과 biphenyl계 혼합 에폭시 수지 조성물의 열적 특성과 난연 특성을 검토하였다. OCN과 biphenyl 에폭시의 부피비에 따라 5가지 조성물을 디자인하였으며, TGA 및 DTG, 그리고 UL-94V 테스트를 통해 난연 효과를 평가하였다. 충전제와 적인의 함량이 증가할수록 열적 성질 및 우수한 난연 효과를 보였으나, 과량의 적인을 적용하였을 경우에는 열안정성의 저하를 유발하였다. 복합재료의 기저 수지호서 OCN/biphenyl 혼합 에폭시를 사용하였을 경우 OCN의 내열특성과 biphenyl 에폭시의 높은 발포 특성에 기인하여 보다 향상된 난연 특성을 확보할 수 있었다. 적인을 적용한 에폭시 수지 조성물의 난연 기구는 표면에서 형성된 발포성 탄화층 (char-layer)의 열적 방어 효과로 판단할 수 있었다.